Patent · US Active

Extended release tablet formulations of flibanserin and method for manufacturing the same

US8545886B2 · kind B2 · utility

13Cited by

44References

22Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Wolfram EISENREICH · Ulm, DE
Thomas Friedl · Seekirchen am Wallersee, AT

Key dates

Filing date	Aug 13, 2007
Grant date	Oct 1, 2013
Priority date	—
Expiry date	Mar 28, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/24
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.